CORONADO, Calif. — IOP reduction was sustained at 2 years in patients with mild to moderate primary open-angle glaucoma who underwent CyPass micro-stent implantation at the same time as cataract surgery in the COMPASS trial, Quang H. Nguyen, MD, and colleagues reported in a poster presented at the American Glaucoma Society meeting.
In the randomized intervention trial, 374 patients underwent the combination of phacoemulsification plus CyPass micro-stent (Alcon) implantation, with 61.2% of those patients maintaining mean IOP between 6 mm Hg and 18 mm Hg at 2 years. Of the 131 patients who underwent phacoemulsification only, 43.5% maintained that mean value. The difference was statistically significant (P = .0005).
Patients were included who had unmedicated diurnal IOP of 21 mm Hg to 33 mm Hg, which was at least 3 mm Hg higher than the medicated IOP measured at the screening visit.
Endpoints at 24 months were proportion of subjects with a 20% or greater reduction in unmedicated diurnal IOP from baseline, mean reduction of unmedicated diurnal IOP from baseline and proportion of eyes with mean unmedicated diurnal IOP between 6 mm Hg and 18 mm Hg.
Postoperative adverse ocular events were comparable in both groups, including secondary surgical interventions.
The COMPASS study “is the first study with 2-year follow-up, baseline and terminal washout to measure true IOP-lowering effect of CyPass when used in conjunction with cataract surgery,” the authors wrote. – by Patricia Nale, ELS
Nguyen QH, et al. Minimally invasive supraciliary microstent for IOP control in combined POAG-cataract surgery: 2-year COMPASS trial results. Poster presented at: American Glaucoma Society annual meeting; March 2-5, 2017; Coronado, Calif.
Nguyen reports he is a consultant and speaker for Alcon.